SEC INSIDER TRANSACTIONS

THERMO FISHER SCIENTIFIC INC. (TMO) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

TMO · THERMO FISHER SCIENTIFIC INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 40 filings · fetched 2026-11-13T20:19:33Z

Recent reported activity

0purchase rows on this page

9sale rows on this page

165matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-28Filed 2026-09-01	Holmes Joseph R.Officer · VP & Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	12.915D	622.18	Direct	Form 4 ↗0000097745-26-000163
2026-08-28Filed 2026-09-01	Holmes Joseph R.Officer · VP & Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	10.567D	622.18	Direct	Form 4 ↗0000097745-26-000163
2026-08-28Filed 2026-09-01	Pettiti GianlucaOfficer · President & COO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. F2 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	F WithholdingCommon Stock · Non-derivative	269.794D	622.18	Direct	Form 4 ↗0000097745-26-000162
2026-08-28Filed 2026-09-01	Pettiti GianlucaOfficer · President & COO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. F2 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	F WithholdingCommon Stock · Non-derivative	249.003D	622.18	Direct	Form 4 ↗0000097745-26-000162
2026-08-28Filed 2026-09-01	Pettiti GianlucaOfficer · President & COO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. F2 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	F WithholdingCommon Stock · Non-derivative	303.639D	622.18	Direct	Form 4 ↗0000097745-26-000162
2026-08-28Filed 2026-09-01	Pettiti GianlucaOfficer · President & COO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026. F2 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	F WithholdingCommon Stock · Non-derivative	212.256D	622.18	Direct	Form 4 ↗0000097745-26-000162
2026-08-28Filed 2026-09-01	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	85.096D	622.18	Direct	Form 4 ↗0000097745-26-000161
2026-08-28Filed 2026-09-01	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	105.403D	622.18	Direct	Form 4 ↗0000097745-26-000161
2026-08-28Filed 2026-09-01	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	116.04D	622.18	Direct	Form 4 ↗0000097745-26-000161
2026-08-28Filed 2026-09-01	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. References:	F WithholdingCommon Stock · Non-derivative	87.03D	622.18	Direct	Form 4 ↗0000097745-26-000161
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F7	M Exercise / conversionStock Option (Right to Buy) · Derivative	275D	0	Direct	Form 4 ↗0001216055-26-000012
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	62D	628.74	Direct	Form 4 ↗0001216055-26-000012
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	79D	628.01	Direct	Form 4 ↗0001216055-26-000012
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	33D	626.59	Direct	Form 4 ↗0001216055-26-000012
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	101D	625.41	Direct	Form 4 ↗0001216055-26-000012
2026-08-24Filed 2026-08-26	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.25 to $627.21, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.43 to $628.34, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.48 to $628.89, inclusive. F6 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F7 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References:	M Exercise / conversionCommon Stock · Non-derivative	275A	309.63	Direct	Form 4 ↗0001216055-26-000012
2026-08-22Filed 2026-08-24	Meyer JamesOfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 19.519 shares acquired under the Issuers employees stock purchase plan on May 15, 2026. F2 Between March 1, 2026 and August 21, 2026, the reporting person acquired 8.34 shares of TMO common stock under the TMO 401(k) plan. References: F1	F WithholdingCommon Stock · Non-derivative	30.945D	629.27	Direct	Form 4 ↗0000097745-26-000153
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F16	M Exercise / conversionStock Option (Right to Buy) · Derivative	10,000D	0	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F14	S Sale (market/private)Common Stock · Non-derivative	321D	629.1	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F13	S Sale (market/private)Common Stock · Non-derivative	2,147D	628.61	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F12	S Sale (market/private)Common Stock · Non-derivative	1,791D	627.39	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F11	S Sale (market/private)Common Stock · Non-derivative	3,014D	626.51	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F10	S Sale (market/private)Common Stock · Non-derivative	2,727D	625.46	Direct	Form 4 ↗0000097745-26-000152
2026-08-21Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References:	M Exercise / conversionCommon Stock · Non-derivative	10,000A	309.63	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F16	M Exercise / conversionStock Option (Right to Buy) · Derivative	10,000D	0	Direct	Form 4 ↗0000097745-26-000152

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.